Evaluation of Pain Treatment After Total Knee Arthroplasty
← catalyst calendarNCT07538570 · readout in 164 d
Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Non randomized · Quadruple · Treatment
Enrollment
60estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-24 | actual | When the study began enrolling |
| Primary completion | 2027-01-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pain
Interventions
- Drug: Suzetrigine — also filed as VX-548, JOURNAVX
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTotal Opioid Usage
measured 24 hours to 168 hours after the first dose of study drug
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed